in CHF m |
Care Chemicals |
Catalysis |
Natural Resources |
Plastics & Coatings |
Total segments |
Corporate |
Total Group |
|||||||||||||||||||||||
|
2015 |
2014 |
2015 |
2014 |
2015 |
2014 |
2015 |
2014 |
2015 |
2014 |
2015 |
2014 |
2015 |
2014 |
||||||||||||||||
|
||||||||||||||||||||||||||||||
Segment sales |
1 446 |
1 514 |
704 |
729 |
1 219 |
1 300 |
2 458 |
2 599 |
5 827 |
6 142 |
|
– |
5 827 |
6 142 |
||||||||||||||||
Sales to other segments |
–1 |
–3 |
– |
|
–2 |
–3 |
–17 |
–20 |
–20 |
–26 |
|
– |
–20 |
–26 |
||||||||||||||||
Total sales |
1 445 |
1 511 |
704 |
729 |
1 217 |
1 297 |
2 441 |
2 579 |
5 807 |
6 116 |
– |
– |
5 807 |
6 116 |
||||||||||||||||
Operating expenses |
–1 225 |
–1 302 |
–565 |
–646 |
–1 044 |
–1 234 |
–2 230 |
–2 314 |
–5 064 |
–5 496 |
–247 |
–95 |
–5 311 |
–5 591 |
||||||||||||||||
Thereof: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Income from associates and joint ventures |
9 |
9 |
18 |
17 |
9 |
3 |
30 |
35 |
66 |
64 |
11 |
11 |
77 |
75 |
||||||||||||||||
Gain from disposals not qualifying as discontinued operations |
– |
|
12 |
|
3 |
5 |
– |
|
15 |
5 |
– |
163 |
15 |
168 |
||||||||||||||||
Restructuring, impairment and transaction-related costs |
–6 |
–2 |
– |
–30 |
–1 |
–96 |
–23 |
–10 |
–30 |
–138 |
–85 |
–90 |
–115 |
–228 |
||||||||||||||||
Operating income |
220 |
209 |
139 |
83 |
173 |
63 |
211 |
265 |
743 |
620 |
–247 |
–95 |
496 |
525 |
||||||||||||||||
Net financial expenses and taxes |
|
|
|
|
|
|
|
|
|
|
|
|
–269 |
–290 |
||||||||||||||||
Net result from continuing operations |
|
|
|
|
|
|
|
|
|
|
|
|
227 |
235 |
||||||||||||||||
Result from discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
|
12 |
–18 |
||||||||||||||||
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
239 |
217 |
||||||||||||||||
Segment assets |
982 |
1 014 |
1 631 |
1 627 |
872 |
997 |
1 700 |
1 889 |
5 185 |
5 527 |
|
|
5 185 |
5 527 |
||||||||||||||||
Segment liabilities |
–200 |
–224 |
–123 |
–107 |
–109 |
–135 |
–228 |
–226 |
–660 |
–692 |
|
|
–660 |
–692 |
||||||||||||||||
Net operating assets |
782 |
790 |
1 508 |
1 520 |
763 |
862 |
1 472 |
1 663 |
4 525 |
4 835 |
– |
– |
4 525 |
4 835 |
||||||||||||||||
Net assets held for sale |
– |
– |
– |
62 |
– |
– |
2 |
2 |
2 |
64 |
– |
–2 |
2 |
62 |
||||||||||||||||
Corporate assets without cash |
|
|
|
|
|
|
|
|
|
|
1 333 |
1 388 |
1 333 |
1 388 |
||||||||||||||||
Corporate liabilities without financial liabilities |
|
|
|
|
|
|
|
|
|
|
–2 054 |
–2 289 |
–2 054 |
–2 289 |
||||||||||||||||
Net debt2 |
|
|
|
|
|
|
|
|
|
|
–1 312 |
–1 263 |
–1 312 |
–1 263 |
||||||||||||||||
Total net assets |
782 |
790 |
1 508 |
1 582 |
763 |
862 |
1 474 |
1 665 |
4 527 |
4 899 |
–2 033 |
–2 166 |
2 494 |
2 733 |
||||||||||||||||
Thereof: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Investments in PPE and intangibles for the period |
97 |
90 |
148 |
49 |
33 |
38 |
78 |
79 |
356 |
256 |
45 |
65 |
401 |
321 |
||||||||||||||||
Investments in associates and joint ventures at the end of the period |
57 |
59 |
187 |
200 |
15 |
19 |
143 |
165 |
402 |
443 |
184 |
192 |
586 |
635 |
||||||||||||||||
Reconciliation of key figures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Operating income |
220 |
209 |
139 |
83 |
173 |
63 |
211 |
265 |
743 |
620 |
–247 |
–95 |
496 |
525 |
||||||||||||||||
Add: systematic depreciation of PPE |
42 |
44 |
33 |
38 |
24 |
26 |
68 |
74 |
167 |
182 |
36 |
39 |
203 |
221 |
||||||||||||||||
Add: impairment |
– |
– |
– |
30 |
– |
87 |
13 |
– |
13 |
117 |
1 |
–1 |
14 |
116 |
||||||||||||||||
Add: amortization of intangible assets |
4 |
4 |
17 |
20 |
11 |
11 |
11 |
11 |
43 |
46 |
11 |
15 |
54 |
61 |
||||||||||||||||
EBITDA1 |
266 |
257 |
189 |
171 |
208 |
187 |
303 |
350 |
966 |
965 |
–199 |
–42 |
767 |
923 |
||||||||||||||||
Add: restructuring, impairment and transaction-related costs |
6 |
2 |
– |
30 |
1 |
96 |
23 |
10 |
30 |
138 |
85 |
90 |
115 |
228 |
||||||||||||||||
Less: impairment (reported under restructuring and impairment) |
– |
– |
– |
–30 |
– |
–87 |
–13 |
– |
–13 |
–117 |
–1 |
1 |
–14 |
–116 |
||||||||||||||||
Less: gain from disposals not qualifying as discontinued operations |
– |
– |
–12 |
– |
–3 |
–5 |
– |
– |
–15 |
–5 |
– |
–163 |
–15 |
–168 |
||||||||||||||||
EBITDA before exceptional items |
272 |
259 |
177 |
171 |
206 |
191 |
313 |
360 |
968 |
981 |
–115 |
–114 |
853 |
867 |
||||||||||||||||
Operating income |
220 |
209 |
139 |
83 |
173 |
63 |
211 |
265 |
743 |
620 |
–247 |
–95 |
496 |
525 |
||||||||||||||||
Add: restructuring, impairment and transaction-related costs |
6 |
2 |
– |
30 |
1 |
96 |
23 |
10 |
30 |
138 |
85 |
90 |
115 |
228 |
||||||||||||||||
Less: gain from disposals not qualifying as discontinued operations |
– |
– |
–12 |
– |
–3 |
–5 |
– |
– |
–15 |
–5 |
– |
–163 |
–15 |
–168 |
||||||||||||||||
Operating income before exceptional items |
226 |
211 |
127 |
113 |
171 |
154 |
234 |
275 |
758 |
753 |
-162 |
-168 |
596 |
585 |
||||||||||||||||